Bolus fibrinolysis: risk, benefit, and opportunities.
University of Alberta, Edmonton, Alberta, Canada. paul.armstrong@ualberta.ca
P W
PW
Armstrong
C
C
Granger
F
F
Van de Werf
D002986:Clinical Trials as Topic; D005342:Fibrinolysis / Q000502:physiology*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous / Q000009:adverse effects; D020300:Intracranial Hemorrhages / Q000209:etiology*; D016017:Odds Ratio; D018570:Risk Assessment
D005343:Fibrinolytic Agents